|
1
|
Lee AW, Lin JC and Ng WT: Current
management of nasopharyngeal cancer. Semin Radiat Oncol.
22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma BB, Hui EP and Chan AT: Systemic
approach to improving treatment outcome in nasopharyngeal
carcinoma: current and future directions. Cancer Sci. 99:1311–1318.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qian W, Liu J, Jin J, Ni W and Xu W:
Arsenic trioxide induces not only apoptosis but also autophagic
cell death in leukemia cell lines via up-regulation of Beclin-1.
Leuk Res. 31:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Basciani S, Vona R, Matarrese P, Ascione
B, Mariani S, Cauda R, Gnessi L, Malorni W, Straface E and Lucia
MB: Imatinib interferes with survival of multi drug resistant
Kaposi’s sarcoma cells. FEBS Lett. 581:5897–5903. 2007.PubMed/NCBI
|
|
5
|
Yang W, Monroe J, Zhang Y, George D,
Bremer E and Li H: Proteasome inhibition induces both pro- and
anti-cell death pathways in prostate cancer cells. Cancer Lett.
243:217–227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar
|
|
7
|
Huang S and Houghton PJ: Targeting mTOR
signaling for cancer therapy. Curr Opin Pharmacol. 3:371–377. 2003.
View Article : Google Scholar
|
|
8
|
Gomez-Pinillos A and Ferrari AC: mTOR
signaling pathway and mTOR inhibitors in cancer therapy. Hematol
Oncol Clin North Am. 26:483–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grzybowska-Izydorczyk O and Smolewski P:
mTOR kinase inhibitors as a treatment strategy in hematological
malignancies. Future Med Chem. 4:487–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
from growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wan X and Helman LJ: The biology behind
mTOR inhibition in sarcoma. Oncologist. 12:1007–1018. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan S: Targeting the mammalian target of
rapamycin (mTOR): a new approach to treating cancer. Br J Cancer.
91:1420–1424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vignot S, Faivre S, Aguirre D and Raymond
E: mTOR targeted therapy of cancer with rapamycin derivatives. Ann
Oncol. 16:525–537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin CI, Whang EE, Donner DB, Du J, Lorch
J, He F, Jiang X, Price BD, Moore FD Jr and Ruan DT: Autophagy
induction with RAD001 enhances chemosensitivity and
radiosensitivity through Met inhibition in papillary thyroid
cancer. Mol Cancer Res. 8:1217–1226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Molinolo AA, Marsh C, El Dinali M, Gangane
N, Jennison K, Hewitt S, Patel V, Seiwert TY and Gutkind JS: mTOR
as a molecular target in HPV-associated oral and cervical squamous
carcinomas. Clin Cancer Res. 18:2558–2568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mabuchi S, Altomare DA, Cheung M, Zhang L,
Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and Testa JR:
RAD001 inhibits human ovarian cancer cell proliferation, enhances
cisplatin-induced apoptosis, and prolongs survival in an ovarian
cancer model. Clin Cancer Res. 13:4261–4270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Götze KS, Hoffmann D, Schätzl HM, Peschel
C, Fend F and Decker T: Fatal Epstein-Barr virus-associated
lymphoproliferative disorder following treatment with a novel mTOR
inhibitor for relapsed chronic lymphocytic leukemia cells.
Haematologica. 92:1282–1283. 2007.
|
|
18
|
Ghayad SE, Bieche I, Vendrell JA, Keime C,
Lidereau R, Dumontet C and Cohen PA: mTOR inhibition reverses
acquired endocrine therapy resistance of breast cancer cells at the
cell proliferation and gene-expression levels. Cancer Sci.
99:1992–2003. 2008.PubMed/NCBI
|
|
19
|
Zitzmann K, De Toni EN, Brand S, Göke B,
Meinecke J, Spöttl G, Meyer HH and Auemhammer CJ: The novel mTOR
inhibitor RAD001 (everolimus) induces antiproliferative effects in
human pancreatic neuroendocrine tumor cells. Neuroendocrinology.
85:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Patel V, Marsh CA, Dorsam RT, Mikelis CM,
Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R,
Molinolo AA and Gutkind JS: Decreased lymphangiogenesis and lymph
node metastasis by mTOR inhibition in head and neck cancer. Cancer
Res. 71:7103–7112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yip WK, Leong VC, Abdullah MA, Yusoff S
and Seow HF: Overexpression of phospho-Akt correlates with
phosphorylation of EGF receptors, FKHR and BAD in nasopharyngeal
carcinoma. Oncol Rep. 19:319–328. 2008.PubMed/NCBI
|
|
22
|
Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng
MH, Cheng SH, Tsao SW and Chan AT: The activity of mTOR inhibitor
RAD001 (everolimus) in nasopharyngeal carcinoma and
cisplatin-resistant cell lines. Invest New Drugs. 28:413–420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beuvink I, Boulay A, Fumagalli S,
Zilbermann F, Ruetz S, O’Reilly T, Natt F, Hall J, Lane HA and
Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to
DNA-damaged induced apoptosis through inhibition of p21
translation. Cell. 120:747–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pinto-Leite R, Arantes-Rodrigues R,
Palmeira C, Gaivão I, Cardoso ML, Colaço A, Santos L and Oliveira
P: Everolimus enhances gemcitabine-induced cytotoxicity in
bladder-cancer cell lines. J Toxicol Environ Health A. 75:788–799.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma
Y and Zhang J: Antitumor effect of the mTOR inhibitor everolimus in
combination with trastuzumab on human breast cancer stem cells in
vitro and in vivo. Tumour Biol. 33:1349–1362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Zhang S, Liu Y, Liu J, Ma Y, Zhu
Y and Zhang J: Effects of the combination of RAD001 and docetaxel
on breast cancer stem cells. Eur J Cancer. 48:1581–1592. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon
YK, Han SW, Song SH, Oh DY, Kim TY and Bang YJ: RAD001 shows
activity against gastric cancer cells and overcomes 5-FU resistance
by downregulating thymidylate synthase. Cancer Lett. 299:22–28.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haritunians T, Mori A, O’Kelly J, Luong
QT, Giles FJ and Koeffler HP: Antiproliferative activity of RAD001
(everolimus) as a single agent and combined with other agents in
mantle cell lymphoma. Leukemia. 21:333–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wanner K, Hipp S, Oelsner M, Ringshausen
I, Bogner C, Peschel C and Decker T: Mammalian target of rapamycin
inhibition induces cell cycle arrest in diffuse large B cell
lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br
J Haematol. 134:475–484. 2006. View Article : Google Scholar
|
|
30
|
Wang ZG, Fukazawa T, Nishikawa T, Watanabe
N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S,
Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N and
Naomoto Y: RAD001 offers a therapeutic intervention through
inhibition of mTOR as a potential strategy for esophageal cancer.
Oncol Rep. 23:1167–1172. 2010.PubMed/NCBI
|
|
31
|
Liu H, Scholz C, Zang C, Schefe JH, Habbel
P, Regierer AC, Schulz CO, Possinger K and Eucker J: Metformin and
the mTOR inhibitor everolimus (RAD001) sensitize breast cancer
cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Anticancer Res. 32:1627–1637. 2012.PubMed/NCBI
|
|
32
|
Cao C, Subhawong T, Albert JM, Kim KW,
Geng L, Sekhar KR, Gi YJ and Lu B: Inhibition of mammalian target
of rapamycin or apoptotic pathway induces autophagy and
radiosensitizes PTEN null prostate cancer cells. Cancer Res.
66:10040–10047. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Altmeyer A, Josset E, Denis JM, Gueulette
J, Slabbert J, Mutter D, Noël G and Bischoff P: The mTOR inhibitor
RAD001 augments radiation-induced growth inhibition in a
hepatocellular carcinoma cell line by increasing autophagy. Int J
Oncol. 41:1381–1386. 2012.PubMed/NCBI
|
|
34
|
Crazzolara R, Bradstock KF and Bendall LJ:
RAD001 (everolimus) induces autophagy in acute lymphoblastic
leukemia. Autophagy. 5:727–728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosich L, Xargay-Torrent S, López-Guerra
M, Campo E, Colomer D and Roué G: Counteracting autophagy overcomes
resistance to everolimus in mantle cell lymphoma. Clin Cancer Res.
18:5278–5289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maycotte P and Thorburn A: Autophagy and
cancer therapy. Cancer Biol Ther. 11:127–137. 2011. View Article : Google Scholar
|
|
37
|
Castedo M, Roumier T, Blanco J, Ferri KF,
Barretina J, Tintignac LA, Andreau K, Perfettini JL, Amendola A,
Nardacci R, Leduc P, Ingber DE, Druillennec S, Roques B, Leibovitch
SA, Vilella-Bach M, Chen J, Este JA, Modjtahedi N, Piacentini M and
Kroemer G: Sequential involvement of Cdk1, mTOR and p53 in
apoptosis induced by the HIV-1 envelope. EMBO J. 21:4070–4080.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li B, Desai SA, MacCorkle-Chosnek RA, Fan
L and Spencer DM: A novel conditional Akt ‘survival switch’
reversibly protects cells from apoptosis. Gene Ther. 9:233–244.
2002.
|
